Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Go back to Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma| ALKERMES (NASDAQ: ALKS) | Delayed: 47.82 +1.80 (3.91%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $46.02 | 52 Week High | $80.71 | |||
| Open | $46.00 | 52 Week Low | $27.14 | |||
| Day High | $48.07 | P/E | 367.85 | |||
| Day Low | $45.47 | EPS | $0.13 | |||
| Volume | 892,882 | |||||
